The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Open accessAbstract
We describe a new mechanism regulating the tumor endothelial barrier and T cell infiltration into tumors. We detected selective expression of the death mediator Fas ligand (FasL, also called CD95L) in the vasculature of human and mouse solid tumors but not in normal vasculature. In these tumors, FasL expression was associated with scarce CD8+ infiltration and a predominance of FoxP3+ T regulatory (Treg) cells. Tumor-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expression in endothelial cells, which acquired the ability to kill effector CD8+ T cells but not Treg cells because of higher levels of c-FLIP expression in Treg cells. In mice, genetic or pharmacologic suppression of FasL produced a substantial increase in the influx of tumor-rejecting CD8+ over FoxP3+ T cells. Pharmacologic inhibition of VEGF and PGE2 produced a marked increase in the influx of tumor-rejecting CD8+ over FoxP3+ T cells that was dependent on attenuation of FasL expression and led to CD8-dependent tumor growth suppression. Thus, tumor paracrine mechanisms establish a tumor endothelial death barrier, which has a critical role in establishing immune tolerance and determining the fate of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Self-citationHMEC-1: Establishment of an Immortalized Human Microvascular Endothelial Cell Line
Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., & Lawley, T. J. (1992) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12613748 · Cited by 1,265
The many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Self-citationHUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
Self-citationConcomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., & Nagata, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2045 · Cited by 508
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Self-citationIn vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 377
Griffioen, A., Damen, C., Blijham, G., & Groenewegen, G. (1996) · Blood · doi:10.1182/blood.v88.2.667.bloodjournal882667 · Cited by 304
Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H., & Groenewegen, G. (1996) · PubMed · Cited by 282
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Restifo, N. P. (2000) · Nature Medicine · doi:10.1038/74955 · Cited by 251
Lurquin, C., Lethé, B., De Plaen, E., Corbière, V., Théate, I., van Baren, N., Coulie, P. G., & Boon, T. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041378 · Cited by 240
Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S., Morrow, J. D., Dey, S. K., & DuBois, R. N. (2003) · PubMed · Cited by 220
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 218
Strauss, L., Bergmann, C., & Whiteside, T. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1469 · Cited by 214
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Bouzin, C., Brouet, A., De Vriese, J., DeWever, J., & Feron, O. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1505 · Cited by 200
Shetty, S., Weston, C. J., Oo, Y. H., Westerlund, N., Stamataki, Z., Youster, J., Hubscher, S. G., Salmi, M., Jalkanen, S., Lalor, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002961 · Cited by 173
Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis
Bajou, K., Peng, H., Laug, W. E., Maillard, C., Noel, A., Foidart, J. M., Martial, J. A., & DeClerck, Y. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.012 · Cited by 161
Huang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156
Zhang, L., Yang, N., Conejo Garcia, J.-R., Mohamed, A., Benencia, F., Rubin, S. C., Allman, D., & Coukos, G. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64505-1 · Cited by 151
Self-citationEpithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams, V. M., Chavez, S. L., Kamsteeg, M., Hanczaruk, B., Schwartz, P. E., Rutherford, T., & Mor, G. (2003) · PubMed · Cited by 139
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
Basu, G. D., Tinder, T. L., Bradley, J. M., Tu, T., Hattrup, C. L., Pockaj, B. A., & Mukherjee, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2391 · Cited by 133
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., & Restifo, N. P. (1999) · PubMed · Cited by 133
Motz, G. T., Eppert, B. L., Sun, G., Wesselkamper, S. C., Linke, M. J., Deka, R., & Borchers, M. T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8036 · Cited by 98
Self-citationTei, K., Kawakami-Kimura, N., Taguchi, O., Kumamoto, K., Higashiyama, S., Taniguchi, N., Toda, K., Kawata, R., Hisa, Y., & Kannagi, R. (2002) · PubMed · Cited by 86
Lam, C.-T., Yang, Z.-F., Lau, C.-K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2802 · Cited by 83
Favre-Félix, N., Fromentin, A., Hammann, A., Solary, É., Martin, F., & Bonnotte, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5023 · Cited by 77
Intratumoral T Cell Subset Ratios and Fas Ligand Expression on Brain Tumor Endothelium
Yu, J. S., Lee, P. K., Ehtesham, M., Samoto, K., Black, K. L., & Wheeler, C. J. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02700020 · Cited by 73
Herrero, R., Kajikawa, O., Matute‐Bello, G., Wang, Y. H., Hagimoto, N., Mongovin, S., Wong, V., Park, D. R., Brot, N., Heinecke, J. W., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43004 · Cited by 66
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
Cipponi, A., Wieërs, G., van Baren, N., & Coulie, P. G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1026-2 · Cited by 60
Angiogenic Profile of Breast Carcinoma Determines Leukocyte Infiltration
Steege, J. C. A. B.-T., Baeten, C. I. M., Thijssen, V. L., Satijn, S., Verhoeven, I. C. L., Hillen, H. F. P., Wagstaff, J., & Griffioen, A. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0742 · Cited by 51
Sata, M., Luo, Z., & Walsh, K. X. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6964 · Cited by 51
Gaugler, M.-H. (2005) · British Journal of Radiology · doi:10.1259/bjr/24511652 · Cited by 48
Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the Heart
Jiang, Y., Jones, S. P., Suhara, T., Greer, J. J. M., Ware, P. D., Nguyen, N. P., Perlman, H., Nelson, D. P., Lefer, D. J., & Walsh, K. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211707200 · Cited by 38
Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy
Donskov, F. N., von der Maase, H., Marcussen, N., Hamilton-Dutoit, S. J., Madsen, H. H. T., Jensen, J. J., & Hokland, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1111 · Cited by 9
Cited by
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Metadata
- Authors
- Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G.
- Venue
- Nature Medicine
- Published
- 2014-05-04
- Volume
- 20
- Issue
- 6
- Pages
- 607-615
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1983517349
- Cited by
- 1,035
- References
- 49
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.